Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.24 +1.6%	$3.28	$2.63 ▼ $4.73	$610.82M	1.45	986,499 shs	544,024 shs
ACAD ACADIA Pharmaceuticals	$14.65 +2.1%	$16.85	$13.40 ▼ $20.68	$2.44B	0.54	1.85 million shs	1.57 million shs
HCM HUTCHMED	$15.20 -2.6%	$14.90	$11.51 ▼ $21.92	$2.65B	0.66	106,682 shs	97,256 shs
IMVT Immunovant	$14.45 +1.4%	$17.73	$12.72 ▼ $34.47	$2.45B	0.81	1.20 million shs	1.27 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.57%	+5.88%	-4.42%	-2.99%	+17.82%
ACAD ACADIA Pharmaceuticals	+2.11%	+0.57%	-14.96%	-23.20%	-12.47%
HCM HUTCHMED	-2.56%	+10.63%	+0.73%	+11.76%	-16.71%
IMVT Immunovant	+1.40%	-2.63%	-25.67%	-38.25%	-49.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.0948 of 5 stars	3.5	0.0	3.3	2.5	0.6
ACAD ACADIA Pharmaceuticals	4.1208 of 5 stars	4.3	1.0	3.4	4.2	2.5
HCM HUTCHMED	2.0836 of 5 stars	3.0	3.0	1.8	0.0	1.9
IMVT Immunovant	1.9272 of 5 stars	4.5	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	69.75% Upside
ACAD ACADIA Pharmaceuticals	2.50	Moderate Buy	$23.93	63.33% Upside
HCM HUTCHMED	2.00	Hold	$19.00	25.00% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	165.28% Upside

Current Analyst Ratings Breakdown

Latest ABUS, IMVT, HCM, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$38.00 ➝ $17.00
4/8/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/28/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/20/2025	IMVT Immunovant	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/20/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
3/19/2025	IMVT Immunovant	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$51.00 ➝ $51.00
3/10/2025	IMVT Immunovant	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/7/2025	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$20.00 ➝ $20.00
3/4/2025	IMVT Immunovant	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	IMVT Immunovant	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$20.00
3/2/2025	IMVT Immunovant	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Mixed ➝ Mixed

(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$6.17M	100.53	N/A	N/A	$0.63 per share	5.14
ACAD ACADIA Pharmaceuticals	$957.80M	2.55	N/A	N/A	$2.63 per share	5.57
HCM HUTCHMED	$630.20M	4.20	$0.62 per share	24.51	$4.27 per share	3.56
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$72.85M	-$0.38	N/A	N/A	N/A	-1,137.65%	-68.18%	-51.55%	5/1/2025 (Estimated)
ACAD ACADIA Pharmaceuticals	-$61.29M	$1.36	18.79	19.28	N/A	13.83%	25.83%	14.71%	5/6/2025 (Estimated)
HCM HUTCHMED	$100.78M	N/A	0.00	10.41	N/A	N/A	N/A	N/A	5/9/2025 (Estimated)
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)

Latest ABUS, IMVT, HCM, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.05	N/A	N/A	N/A	$239.32 million	N/A
5/1/2025	Q1 2025	ABUS Arbutus Biopharma	-$0.09	N/A	N/A	N/A	$2.54 million	N/A
3/27/2025	Q4 2024	ABUS Arbutus Biopharma	-$0.08	-$0.07	+$0.01	-$0.07	$2.20 million	$1.57 million
2/10/2025	Q3 2025	IMVT Immunovant	-$0.68	-$0.76	-$0.08	-$0.76	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	7.02	7.02
ACAD ACADIA Pharmaceuticals	N/A	2.29	2.11
HCM HUTCHMED	0.07	2.81	2.68
IMVT Immunovant	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
ACAD ACADIA Pharmaceuticals	96.71%
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
ACAD ACADIA Pharmaceuticals	28.30%
HCM HUTCHMED	3.60%
IMVT Immunovant	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.48 million	181.91 million	Optionable
ACAD ACADIA Pharmaceuticals	510	166.79 million	119.30 million	Optionable
HCM HUTCHMED	1,760	174.32 million	168.04 million	Not Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable

ABUS, IMVT, HCM, and ACAD Headlines

Recent News About These Companies

Immunovant's (IMVT) "Neutral" Rating Reiterated at UBS Group

April 24 at 8:11 AM | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) is Alpine Global Management LLC's 2nd Largest Position

April 24 at 7:14 AM | marketbeat.com

All change at Immunovant as Pete Salzmann retires

April 23 at 2:27 PM | thepharmaletter.com

Immunovant (NASDAQ:IMVT) Shares Gap Down - Here's Why

April 23 at 12:36 PM | marketbeat.com

Immunovant downgraded to Neutral from Buy at UBS

April 23 at 8:34 AM | markets.businessinsider.com

UBS Downgrades Immunovant (IMVT)

April 23 at 8:34 AM | msn.com

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Rock Springs Capital Management LP

April 23 at 6:56 AM | marketbeat.com

Invesco Ltd. Has $12.49 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT)

April 23 at 3:41 AM | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) Short Interest Update

April 22 at 2:48 PM | marketbeat.com

22,740 Shares in Immunovant, Inc. (NASDAQ:IMVT) Acquired by XTX Topco Ltd

April 22 at 4:15 AM | marketbeat.com

Roivant brings rare disease program closer as Immunovant CEO retires

April 22 at 1:24 AM | endpts.com

Immunovant appoints Eric Venker as CEO, Girao as CFO

April 22 at 1:24 AM | markets.businessinsider.com

Immunovant narrows R&D focus as Roivant execs take CEO, CFO posts

April 22 at 1:24 AM | fiercebiotech.com

Immunovant, Inc. (NASDAQ:IMVT) Holdings Raised by Jump Financial LLC

April 20, 2025 | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $44,565.77 in Stock

April 18, 2025 | insidertrades.com

Affinity Asset Advisors LLC Sells 203,000 Shares of Immunovant, Inc. (NASDAQ:IMVT)

April 17, 2025 | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Russell Investments Group Ltd.

April 16, 2025 | marketbeat.com

20,573 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by F M Investments LLC

April 14, 2025 | marketbeat.com

29,233 Shares in Immunovant, Inc. (NASDAQ:IMVT) Purchased by ExodusPoint Capital Management LP

April 14, 2025 | marketbeat.com

Fmr LLC Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT)

April 13, 2025 | marketbeat.com

Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 28,094 Shares of Stock

April 12, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS, IMVT, HCM, and ACAD Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.24 +0.05 (+1.57%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$3.24 0.00 (0.00%)

As of 04/23/2025 07:19 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ACADIA Pharmaceuticals NASDAQ:ACAD

$14.65 +0.30 (+2.11%)

Closing price 04/23/2025 03:58 PM Eastern

Extended Trading

$14.19 -0.46 (-3.16%)

As of 08:52 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

HUTCHMED NASDAQ:HCM

$15.20 -0.40 (-2.56%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$15.19 -0.01 (-0.07%)

As of 04/23/2025 04:05 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$14.45 +0.20 (+1.40%)

Closing price 04/23/2025 04:00 PM Eastern

Extended Trading

$14.50 +0.05 (+0.35%)

As of 08:27 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time